Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Investig Drugs. 2003 Feb;4(2):210-3.

HPV vaccine MedImmune/GlaxoSmithKline.

Author information

1
Novartis Research Institute, PO Box 80, Brunner Strasse 59, 1235 Vienna, Austria. andreas.billich@pharma.novartis.com

Abstract

MedImmune, in collaboration with GlaxoSmithKline, is developing a vaccine consisting of self-assembling, virus-like particles for the prevention of human papillomavirus (HPV) infection of the genital tract and associated cervical cancer. The vaccine candidates include the prototype vaccine, MEDI-501 (a vaccine directed against HPV-11), MEDI-503 (directed against HPV-16) and MEDI-504 (directed against HPV-18). Following phase I studies, the HPV-16 and HPV-18 components were combined into a multivalent vaccine for subsequent trials; this vaccine is known as MEDI-517. Phase II trials of MEDI-517 were initiated by January 2000 and are currently ongoing.

PMID:
12669384
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center